These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 5371784)

  • 1. [On the treatment of visceral leishmaniasis in dogs with massive doses of solusurmin].
    Fuzailov IuM; Ibragimov II
    Med Parazitol (Mosk); 1969; 38(5):615-6. PubMed ID: 5371784
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of visceral leishmaniasis in patients with antimonials: is there a maximal dose?].
    Llorens Soriano P; Vicente Ull R; Paricio Blasco A; Cervera Juan A; Rubio Rodrigo MJ
    An Med Interna; 1999 Nov; 16(11):602. PubMed ID: 10638007
    [No Abstract]   [Full Text] [Related]  

  • 3. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Santos J; Rivero A; Márquez M
    An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659
    [No Abstract]   [Full Text] [Related]  

  • 4. [Kala-azar in childhood].
    Ballin A; Theodor R; Boichis H; Rotem Y; Altman G
    Harefuah; 1980 Jun; 98(11-12):501-3. PubMed ID: 7203192
    [No Abstract]   [Full Text] [Related]  

  • 5. The irreplaceable image: Acute toxicity in erythroid bone marrow progenitors after antimonial therapy.
    Hernández JA; Navarro JT; Force L
    Haematologica; 2001 Dec; 86(12):1319. PubMed ID: 11726328
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
    Chapman WL; Hanson WL; Alving CR; Hendricks LD
    Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Visceral leishmaniases].
    Rosenthal E; Marty P
    Rev Prat; 2004 Dec; 54(20):2211-6. PubMed ID: 15736529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral leishmaniasis therapy.
    Cascio G; Titone L
    J Chemother; 1989 Jul; 1(4 Suppl):956-9. PubMed ID: 16312721
    [No Abstract]   [Full Text] [Related]  

  • 10. Visceral leishmaniasis (kala-azar) and pregnancy.
    Figueiró-Filho EA; Duarte G; El-Beitune P; Quintana SM; Maia TL
    Infect Dis Obstet Gynecol; 2004; 12(1):31-40. PubMed ID: 15460194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The level of antimony in dogs with visceral leishmaniasis treated with solusurmin].
    FUZAILOV IuM
    Med Parazitol (Mosk); 1962; 31():723-7. PubMed ID: 13945955
    [No Abstract]   [Full Text] [Related]  

  • 12. Visceral leishmaniasis and disseminated intravascular coagulation in a dog.
    Font A; Gines C; Closa JM; Mascort J
    J Am Vet Med Assoc; 1994 Apr; 204(7):1043-4. PubMed ID: 8045804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B.
    Bodhe PV; Pathare AV; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 1996 Mar; 44(3):222. PubMed ID: 9251329
    [No Abstract]   [Full Text] [Related]  

  • 14. [Visceral leishmaniasis refractory to treatment: the efficacy of amphotericin B].
    Pérez Brea A; Ruiz Moreno M; Leal Orozco A; Escorihuela Esteban R; Otero Fraguas M
    An Esp Pediatr; 1996 Feb; 44(2):161-3. PubMed ID: 8830578
    [No Abstract]   [Full Text] [Related]  

  • 15. [Neurological toxicity from pentavalent antimonials during the treatment of visceral leishmaniasis].
    Laguna del Estal P; Calabrese S; Zabala JA; Martín T
    Med Clin (Barc); 1994 Feb; 102(7):276-7. PubMed ID: 8170219
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antimony content of the thyroid of man and animals undergoing visceral leishmaniasis treatment with the organic compound of antimony, stibogluconate sodium].
    Fuzaĭlov IuM
    Med Parazitol (Mosk); 1982; 51(1):62-5. PubMed ID: 6278277
    [No Abstract]   [Full Text] [Related]  

  • 17. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
    Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW
    Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral leishmaniasis in an English girl.
    Chapman RL
    Proc R Soc Med; 1973 Nov; 66(11):1110. PubMed ID: 4777030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.